All In Biotech

Drug Trial Radar · NCT04420689

Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

Phase 1/2 Trial of ALM-488 in Patients Undergoing Head & Neck Surgery

Last checked: Nov 19, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

27

Actual

Start

Jun 18, 2020

Primary completion

Jun 25, 2021

Study completion Feb 15, 2022

Sponsor

Lead sponsor
Alume Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jun 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bevonescein to Highlight Nerves in Patients Undergoing Head \& Neck Surgery

Conditions

  • Parotid Neoplasm
  • Thyroid Neoplasms
  • Head and Neck Neoplasms
  • Surgery
  • Nerve Injury
  • Imaging

Interventions

  • BevonesceinDrug

    Bevonescein Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - The Number of Patients With ALM-488 Related Adverse EventsTime frame: 28 (+5) days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Diego

    San Diego, California

  • Stanford University

    Stanford, California

  • Harvard-Mass Eye & Ear

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.